Возможности телмисартана в АНГИО- и КАрдиопротекции и улучшении показателей углеводного обмена при нарушении толерантности к глюкозе

артериальная гипертензия, метаболический синдром, телмисартан

1. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003; 108: 1541-5.

2. Grassi G, Seravalle G, Dell'Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21.

3. Nishimura H, Sanaka T, Tanihata Y et al. Losartan Elevates the Serum High-Molecular Weight-Adiponectin Isoform and Concurrently Improves Insulin Sensitivity in Patients with Impaired Glucose Metabolism. Hypertens Res 2008; 31: 1611-8.

4. Sasaki T, Noda Y, Yasuoka Y et al. Comparison of the Effects of Telmisartan and Olmesartan on Home Blood Pressure, Glucose, and Lipid Profiles in Patients with Hypertension, Chronic Heart Failure, and Metabolic Syndrome. Hypertens Res 2008; 3: 921-9.

5. Derosa G, Cicero A, D'angelo D et al. Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-a. Hypertens Res 2006; 29: 849-56.

6. Benson SC, Pershadsingh HA, ITO CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity. Hypertension 2004; 43: 1-10.

7. Vitale C, Mercuro G, Castiglioni C et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 15 (4): 6.